Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines

International Journal of Cancer

Volumn 71, Issue 6, 1997, Pages 1103-1108

  Iacopino, Fortunata ^a   Cuna, Gioacchino Robustelli Della ^b   Sica, Gigliola ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HORMONE RECEPTOR; MEDROXYPROGESTERONE ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON-ALPHA; MEDROXYPROGESTERONE 17-ACETATE; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 1842366062     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970611)71:6<1103::AID-IJC29>3.0.CO;2-C     Document Type: Article

References (27)

1. CAILLEAU, R., OLIVÉ, M. and CRUCIGER, Q.V.J., Long-term human breast-carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro. 14, 911-915 (1978).
2. DESZ, H., LECHLEITER, M., MARTH, C., DAXENBICHLER, G., GASTL, G. and BRAUNSTEINER, H., Effect of human recombinant alpha-2-and gamma Interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J. Interferon Res., 5, 147-157 (1985).
3. DORR, R.T., Interferon-α in malignant and viral diseases. A review. Drugs. 45, 177-211 (1993).
4. ENGEL, L.W., YOUNG, N.A., TRALKA, T.S., LIPPMAN, M.E., O'BRIEN, S.J. and JOYCE, M.J., Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res., 38, 3352-3364 (1978).
5. FINTER, N.B., Why are there so many sub-types of alpha-interferons? J. Interferon Res., Special issue, 185-194 (1991).
6. FOOLER, W.E., PEARSON, J.W., VOLKER, K., ARIYOSHI, K., WATABE, H., RIGGS, C.W., WILTROUT, R.H. and LONGO, D.L., Enhancement by recombinant human Interferon alpha of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J. nat. Cancer Inst., 87, 94-104 (1995).
7. GIBELLI, N., ZIBERA, C., SICA, G., CARBONE, M., PEDRAZZOLI, P. and ROBUSTELLI DELLA CUNA, G., Morphological and biochemical features of a medroxyprogesterone-acetate-(MPA)-resistant MCF-7 breast-cancer cell line. Anticancer Res., 14, 37-44 (1994).
8. 2a. J. 7 Interferon Res., 9 (suppl 1), 9-15 (1989).
9. KANG, Y. and PERRY, R.R., Moduialory effects of tamoxifen and recombinant human α-interferon on doxorubicin resistance. Cancer Res., 53, 3040-3045 (1993).
10. KONTSEK, P., Human type-1 interferons: stmcture and function. Acta Virologica, 38, 345-360 (1994).
11. MILELLA, M., ANTONELLI, G., SANTANTONIO, T., GIANNELLI, G., CURRENTI, M., MONNO, L., TURRIZIANI, O., PASTORE, G. and DIANZANI, F., Treatment with natural IFN of hepatitis-C patients with or without antibodies to recombinant IFN. Hepato-gastroenterol., 42, 201-204 (1995).
12. NATOLI, C., SICA, G., NATOLI, V., SERRA, A. and IACOBELLI, S., Two new estrogen-supersensitive variants of the MCF-7 human breast-cancer cell line. Breast Cancer Res. Treat., 3, 23-32 (1983).
13. OSTERBORG, A., ENGMAN, K., BJOREMAN, M., CARLSON, K., KIMBY, E., OHRLING, M., SAMUELSSON, J., OSBY, E. and MELLSTEDT, H., Patients treated with natural (leukocyte-derived) Interferon (IFN)-α do not develop antibodies. Letters to the Editors. Europ. J. Haematol., 47, 234-235 (1991).
14. PESTK, S. and LANGER, J.A., Interferons and their actions. Ann. Rev. Biochem., 56, 727-777 (1987).
15. PRUMMER, O., Interferon-alpha antibodies in patients with renal-cell carcinoma treated with recombinant interferon-alpha-2a in a adjuvant multicenter trial. Cancer, 71, 1828-1834 (1993).
16. ROSENBLUM, M.G. and GUTTERMAN, J.U., Synergistic anti-proliferative activity ot leukocyte mterferon in combination with α-difluommethylornitnine against human cells in culture. Cancer Res., 44, 2339-2340 (1984).
17. SCALA, S., PACELLI, R., IAFFAIOLI, R.V., NORMANNO, N., PEPE, S., FRASCI, G. GENUA, G., TSURUO, T., TAGLIAFERRI, P. and BIANCO, A.R., Reversal of adriamycm resistance by recombinant α-interferon in multidrug-resistant human colon-carcinoma LoVo-doxorubicin cells. Cancer Res., 51, 4898-4902 (1991).
18. SICA., G., IACOPINO, F. and RECCHIA, F., Interferon and hormone-sensitivity of endocrine-related tumors. Review paper. Anti-Cancer Drugs, 7, 1-11 (1996).
19. SICA, G., IACOPINO, F., ROBUSTELLI DEELA CUNA, G. and MARCHETTI, P. Reeombmam imerferon-α2b affects proliferation, steroid receptors and sensitivity to tamoxifen of cultured breast-cancer cells (CG-5). Anti-Cancer Drugs, 3, 147-153 (1992).
20. SICA, G., NATOLI, V., PELLEGRINI, A. and ROBUSTELLI DELLA CUNA, G., The anti-proliferative effect of lamoxifen and medroxyprogesterone acetate in breast-cancer cells is potentiated by natural beta-interferon. In: E.E. Baulieu, S. Iacobelli and W.L. McGuire (eds.), Endocrinology and malig- nancy: basic and clinical issues, pp. 130-135. Parthenon Publishing, Carnforth (1987).
21. SICA, G., NATOLI, V., STELLA, C. and DEL BIANCO, S., Effect of natural beta-mterteron on cell proliferation and steroid receptor level in human breast-cancer cells. Cancer, 60, 2419-2423 (1987).
22. SOULE, H.D., VASQUSZ, J., LONG, A. and ALBERT, B.M., A human cell line from a pleural effusion derived from brest-cancer cells. J. nat. Cancer Inst., 51, 1409-1416 (1973).
23. STEIS, R.G., SMITH, J.W., URBA, W.J., CLARK, J.W., ITRI, L.M., EVANS, L.M., SCHOENBERGER, C. and LONGO, D.L., Resistance to recombinant Interferon alpha 2a in hairy-cell leukemia associated with neutralizing anti-interferon anubodies. New Engl. J. Med., 318, 1409-1413 (1988).
24. TAYLOR-PAPADIMITRIOU, J., SHEARER, M., BALKWILL, F.R. and FANTES, K.H., Effects of HuIFN-α2 and HuIFN-α (Namalwa) on breast-cancer cells grown in cultureand as xenografts in the nude mouse. J. Interferon Res. 2, 479-491 (1982).
25. VON Wussow, P., FREUND, M., BLOCK, B., DEIDRICH, H., POLIDOWA, H. and DEICHER, H., Clinical significance of anti-IFN-α antibody titres during Interferon therapy. Lancet, vii, 635-636 (1987).
26. 2a, Lancet, vi, 882-883 (1988).
27. WADLER, S. and SCHWARTZ, E.L., Anti-neoplastic activity of the combination of interteron and cytotoxic agents against experimental and human malignancies: a review. Cancer Res., 50, 3473-3486 (1990).